Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
{{output}}
Purpose: Direct real-world comparisons between osimertinib and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are lacking, particularly regarding the comparative effectiveness, safety,... ...
